463 related articles for article (PubMed ID: 15824291)
1. A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism.
Wells PS; Anderson DR; Rodger MA; Forgie MA; Florack P; Touchie D; Morrow B; Gray L; O'Rourke K; Wells G; Kovacs J; Kovacs MJ
Arch Intern Med; 2005 Apr; 165(7):733-8. PubMed ID: 15824291
[TBL] [Abstract][Full Text] [Related]
2. Tinzaparin in outpatients with pulmonary embolism or deep vein thrombosis.
Dager WE; King JH; Branch JM; Chow SL; Ferrer RE; Pak S; Togioka PY; White RH
Ann Pharmacother; 2005; 39(7-8):1182-7. PubMed ID: 15956232
[TBL] [Abstract][Full Text] [Related]
3. Selecting an anticoagulant for recurrent venous thromboembolism in cancer.
Goodin S
Am J Health Syst Pharm; 2005 Nov; 62(22 Suppl 5):S10-3. PubMed ID: 16286363
[TBL] [Abstract][Full Text] [Related]
4. Outpatient treatment of pulmonary embolism with dalteparin.
Kovacs MJ; Anderson D; Morrow B; Gray L; Touchie D; Wells PS
Thromb Haemost; 2000 Feb; 83(2):209-11. PubMed ID: 10739374
[TBL] [Abstract][Full Text] [Related]
5. Tinzaparin sodium: a review of its use in the prevention and treatment of deep vein thrombosis and pulmonary embolism, and in the prevention of clotting in the extracorporeal circuit during haemodialysis.
Hoy SM; Scott LJ; Plosker GL
Drugs; 2010 Jul; 70(10):1319-47. PubMed ID: 20568836
[TBL] [Abstract][Full Text] [Related]
6. Community-based treatment of venous thromboembolism with a low-molecular-weight heparin and warfarin.
Hyers TM; Spyropoulos AC;
J Thromb Thrombolysis; 2007 Dec; 24(3):225-32. PubMed ID: 17334932
[TBL] [Abstract][Full Text] [Related]
7. Structured benefit-risk assessment for enoxaparin, in the context of its label extension, for the extended treatment of deep vein thrombosis and pulmonary embolism, and prevention of its recurrence in patients with active cancer.
Kürzinger ML; El-Haddad C; Gouin-Soboleva T; Fazekas Z; Granados D; Benito-Garcia E; Djoudi Y
Pharmacoepidemiol Drug Saf; 2024 May; 33(5):e5795. PubMed ID: 38680090
[TBL] [Abstract][Full Text] [Related]
8. Low-molecular-weight heparins in the treatment of deep-vein thrombosis.
Martineau P; Tawil N
Ann Pharmacother; 1998 May; 32(5):588-98, 601. PubMed ID: 9606481
[TBL] [Abstract][Full Text] [Related]
9. Tinzaparin sodium: a low-molecular-weight heparin.
Neely JL; Carlson SS; Lenhart SE
Am J Health Syst Pharm; 2002 Aug; 59(15):1426-36. PubMed ID: 12166042
[TBL] [Abstract][Full Text] [Related]
10. Should patients with deep vein thrombosis alone be treated as those with concomitant asymptomatic pulmonary embolism? A prospective study.
Monreal M; Büller H; Lensing AW; Bonet M; Roncales J; Muchart J; Fraile M
Thromb Haemost; 2002 Dec; 88(6):938-42. PubMed ID: 12529742
[TBL] [Abstract][Full Text] [Related]
11. Deferment of objective assessment of deep vein thrombosis and pulmonary embolism without increased risk of thrombosis: a practical approach based on the pretest clinical model, D-dimer testing, and the use of low-molecular-weight heparins.
Siragusa S; Anastasio R; Porta C; Falaschi F; Pirrelli S; Palmieri P; Gamba G; Granzow K; Malato A; Minardi V; Tatoni P; Bressan MA; Mariani G
Arch Intern Med; 2004 Dec 13-27; 164(22):2477-82. PubMed ID: 15596639
[TBL] [Abstract][Full Text] [Related]
12. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
Holzheimer RG
Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
[TBL] [Abstract][Full Text] [Related]
13. Tinzaparin sodium: a review of its pharmacology and clinical use in the prophylaxis and treatment of thromboembolic disease.
Cheer SM; Dunn CJ; Foster R
Drugs; 2004; 64(13):1479-502. PubMed ID: 15212562
[TBL] [Abstract][Full Text] [Related]
14. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.
Lee AYY; Kamphuisen PW; Meyer G; Bauersachs R; Janas MS; Jarner MF; Khorana AA;
JAMA; 2015 Aug; 314(7):677-686. PubMed ID: 26284719
[TBL] [Abstract][Full Text] [Related]
15. Long-term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial.
Daskalopoulos ME; Daskalopoulou SS; Tzortzis E; Sfiridis P; Nikolaou A; Dimitroulis D; Kakissis I; Liapis CD
Eur J Vasc Endovasc Surg; 2005 Jun; 29(6):638-50. PubMed ID: 15878544
[TBL] [Abstract][Full Text] [Related]
16. Outpatient treatment of patients with pulmonary embolism.
Wells PS; Büller HR
Semin Vasc Med; 2001 Nov; 1(2):229-34. PubMed ID: 15199507
[TBL] [Abstract][Full Text] [Related]
17. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin: a comparison of patient self-injection with homecare injection.
Wells PS; Kovacs MJ; Bormanis J; Forgie MA; Goudie D; Morrow B; Kovacs J
Arch Intern Med; 1998 Sep; 158(16):1809-12. PubMed ID: 9738611
[TBL] [Abstract][Full Text] [Related]
18. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism.
Kearon C; Ginsberg JS; Julian JA; Douketis J; Solymoss S; Ockelford P; Jackson S; Turpie AG; MacKinnon B; Hirsh J; Gent M;
JAMA; 2006 Aug; 296(8):935-42. PubMed ID: 16926353
[TBL] [Abstract][Full Text] [Related]
19. Tinzaparin versus dalteparin for periprocedure prophylaxis of thromboembolic events in hemodialysis patients: a randomized trial.
Rodger MA; Ramsay T; MacKinnon M; Westphal M; Wells PS; McCormick B; Knoll G
Am J Kidney Dis; 2012 Sep; 60(3):427-34. PubMed ID: 22480794
[TBL] [Abstract][Full Text] [Related]
20. Frequency of pulmonary embolism in patients who have iliofemoral deep vein thrombosis and are treated with once- or twice-daily low-molecular-weight heparin.
Partsch H; Kechavarz B; Mostbeck A; Köhn H; Lipp C
J Vasc Surg; 1996 Nov; 24(5):774-82. PubMed ID: 8918323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
